Last reviewed · How we verify
JMT202
At a glance
| Generic name | JMT202 |
|---|---|
| Sponsor | Shanghai JMT-Bio Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia (PHASE1, PHASE2)
- A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JMT202 CI brief — competitive landscape report
- JMT202 updates RSS · CI watch RSS
- Shanghai JMT-Bio Inc. portfolio CI